Loading...
•
Mar 31, 2024
Esperion Q1 2024 Earnings Report
Esperion's Q1 2024 financial performance was marked by substantial revenue growth and strategic advancements.
Key Takeaways
Esperion reported a remarkable 467% year-over-year increase in total revenue, reaching $137.7 million in Q1 2024. This growth was driven by a 46% increase in U.S. net product revenue and a significant rise in collaboration revenue. The company also achieved FDA approval for expanded labels for NEXLETOL and NEXLIZET, positioning it for further growth.
Total revenue grew by 467% year-over-year to $137.7 million.
U.S. net product revenue increased by 46% year-over-year to $24.8 million.
Retail prescription equivalents grew by 43% year-over-year and 6% quarter-over-quarter.
FDA approved expanded labels for NEXLETOL and NEXLIZET, allowing for cardiovascular risk reduction indications.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
The company still expects full year 2024 operating expenses to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income